Wagenblast Jens, Hambek Markus, Baghi Mehran, Knecht Rainald
ENT Department, Medical School, Goethe University, 60590 Frankfurt am Main, Germany.
Anticancer Res. 2008 Mar-Apr;28(2A):687-92.
Overexpression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinoma (HNSCC) has often been correlated with poor prognosis. Recent investigations have shown that the proteasome inhibitor bortezomib exhibits a high antiproliferative and apoptotic activity in HNSCC cell lines. The present study investigated whether bortezomib has an effect on EGFR expression in different squamous cell carcinoma cell lines.
Six EGF-stimulated or non-stimulated squamous carcinoma cell lines were treated with bortezomib. Western blots were performed to determine EGFR expression. For statistical analysis, a Wilcoxon test for matched pairs (dependent samples) was performed using SPSS 13.0 software for Windows.
Changes in EGFR expression after bortezomib treatment in EGF non-stimulated and EGF-stimulated squamous carcinoma cell lines failed to reach statistical significance in either experimental group (p > 0.05).
Given the high expression of EGFR in head and neck tumors, further investigations should address the question whether the apoptotic activity of bortezomib can be enhanced by adding an anti-EGFR antibody.
表皮生长因子受体（EGFR）在头颈部鳞状细胞癌（HNSCC）中的过表达常与预后不良相关。最近的研究表明，蛋白酶体抑制剂硼替佐米在HNSCC细胞系中表现出高抗增殖和凋亡活性。本研究调查了硼替佐米对不同鳞状细胞癌细胞系中EGFR表达是否有影响。
用硼替佐米处理6种经表皮生长因子（EGF）刺激或未刺激的鳞状癌细胞系。进行蛋白质印迹法以确定EGFR表达。为进行统计分析，使用适用于Windows的SPSS 13.0软件进行配对（相关样本）的Wilcoxon检验。
在两个实验组中，硼替佐米处理后，EGF未刺激和EGF刺激的鳞状癌细胞系中EGFR表达的变化均未达到统计学显著性（p>0.05）。
鉴于头颈部肿瘤中EGFR的高表达，进一步的研究应探讨通过添加抗EGFR抗体是否可以增强硼替佐米的凋亡活性这一问题。
